Journal article
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase 3, randomised, placebo controlled, active reference BE OPTIMAL study
- Abstract:
-
Objectives: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17F in addition to IL‑17A. BKZ treatment has demonstrated superior efficacy versus placebo (PBO) at Week 16 in biologic disease‑modifying antirheumatic drug (DMARD)‑naïve patients with active psoriatic arthritis (PsA). Here, we report longer‑term efficacy and safety to Week 52.
Methods: BE OPTIMAL (NCT03895203) comprised a 16‑week, double‑blind, p...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Accepted manuscript, pdf, 442.8KB, Terms of use)
-
- Publication website:
- https://ard.bmj.com/content/82/Suppl_1/1133
Authors
Bibliographic Details
- Publisher:
- BMJ Publishing Group
- Journal:
- Annals of the Rheumatic Diseases More from this journal
- Volume:
- 82
- Issue:
- S1
- Pages:
- 1133-1134
- Publication date:
- 2023-05-30
- Acceptance date:
- 2023-07-14
- EISSN:
-
1468-2060
- ISSN:
-
0003-4967
Item Description
- Language:
-
English
- Keywords:
- Pubs id:
-
1492958
- Local pid:
-
pubs:1492958
- Deposit date:
-
2023-07-17
Terms of use
- Copyright holder:
- Mcinnes et al
- Copyright date:
- 2023
- Rights statement:
- © Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from BMJ Publishing Group at: https://ard.bmj.com/content/82/Suppl_1/1133
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record